-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – iopofosine i-131 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Iopofosine I-131 in Solid Tumor Drug Details:Iopofosine I-131 (CLR-131) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Brain Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Iopofosine I-131 in Brain TumorDrug Details:Iopofosine I-131 (CLR-131) is under development for the treatment of waldenstrom...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Pediatric Diffuse Intrinsic Pontine Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Pediatric Diffuse Intrinsic Pontine Glioma Drug Details: Iopofosine I-131 (CLR-131) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Multiple Myeloma (Kahler Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Multiple Myeloma (Kahler Disease) Drug Details: Iopofosine I-131 (CLR-131) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Relapsed Multiple Myeloma Drug Details: Iopofosine I-131 (CLR-131) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Refractory Multiple Myeloma Drug Details: Iopofosine I-131 (CLR-131) is under development for...
-
Product Insights
![]()
Switzerland Sparkling Wine market dynamics
Consumers' preferences for wines and spirits are most heavily influenced by novel flavors, premium ingredients, product prices, and packaging. However, manufacturers continue to launch and sell products based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Wines and spirits manufacturers can benefit from the unique intelligence provided by the GlobalData Consumer Intelligence platform, covering more than 2 million products to identify, anticipate, and implement important business choices. GlobalData's new report titled "Switzerland Sparkling Wine market dynamics"...
-
Company Profile
![]()
Cellectar Biosciences Inc – Company Profile
Cellectar Biosciences Inc (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product includes CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – CLR-325
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CLR-325 Drug Details CLR-325 is under development for the treatment of chronic stable heart...
-
Product Insights
![]()
Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Familial Amyloid Neuropathies Pipeline Drugs Market Report Overview Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins, and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness, and fainting. The Familial Amyloid Neuropathies pipeline drugs market research report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.